Skip Navigation


Annals of Oncology Advance Access originally published online on July 8, 2008
Annals of Oncology 2008 19(9):1655-1656; doi:10.1093/annonc/mdn408
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
19/9/1655    most recent
mdn408v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Mego, M.
Right arrow Articles by Mardiak, J.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mego, M.
Right arrow Articles by Mardiak, J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oxfordjournals.org

letters to the editor

Sunitinib in the treatment of tubulocystic carcinoma of the kidney. A case report

The first 10% of the full text of this article appears below.

Collecting (Bellini) duct carcinoma (CDC) of the kidney is a rare variant of kidney carcinoma. It is associated with aggressive course and poor prognosis. CDC represents 1%–3% of renal malignancies and affects more often young males, with median age of 43 years [1]. It is often already metastasized at the time of diagnosis. It . . . [Full Text of this Article]

M. Mego1,*, Z. Sycova-Mila2, K. Rejlekova, B. Rychly3, J. Obertova1, J. Rajec1, O. Hes4 and J. Mardiak2

1 Department of Medical Oncology, Comenius University, School of Medicine, Bratislava, Slovakia
2 Department of Medical Oncology, National Cancer Institute, Bratislava, Slovakia
3 Department of Pathology, Slovak Medical University, Bratislava, Slovakia
4 Department of Pathology, Charles University Hospital, Plzen, Czech Republic

* E-mail: misomego@gmail.com


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?